Publications by authors named "Yann Hyvert"

Claim this Profile
S
Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials.
Xavier Montalban, Patrick Vermersch, Douglas L Arnold, Amit Bar-Or, Bruce A C Cree, Yann Hyvert

Lancet Neurol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety results after >3.5 years of treatment with the Bruton's tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study.
Xavier Montalban, Karolina Piasecka-Stryczynska, Jens Kuhle, Pascal Benkert, Douglas L Arnold, Yann Hyvert

Mult Scler· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Evobrutinib on Slowly Expanding Lesion Volume in Relapsing Multiple Sclerosis: A Post Hoc Analysis of a Phase 2 Trial.
Douglas L Arnold, Colm Elliott, Emily C Martin, Yann Hyvert, Davorka Tomic

Neurology· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody response to SARS-CoV-2 vaccines in patients with relapsing multiple sclerosis treated with evobrutinib: A Bruton's tyrosine kinase inhibitor.
Amit Bar-Or, Anne H Cross, Anthony L Cunningham, Yann Hyvert, Andrea Seitzinger

Mult Scler· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacodynamic biomarkers of long-term interferon beta-1a therapy in REFLEX and REFLEXION.
Mark S Freedman, Jérôme Wojcik, Kristina H Holmberg, Markus Fluck, Mauro D'Antonio, Yann Hyvert

J Neuroimmunol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subgroup analysis of clinical and MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study.
Bruce A C Cree, James D Bowen, Hans-Peter Hartung, Patrick Vermersch, Bruce Hughes, Yann Hyvert

Mult Scler Relat Disord· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study.
Mark S Freedman, Patricia K Coyle, Giancarlo Comi, Susan L Scarberry, Doris Damian, Yann Hyvert

Mult Scler J Exp Transl Clin· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers.
Olaf Stuve, Per Soelberg Soerensen, Thomas Leist, Gavin Giovannoni, Yann Hyvert

Ther Adv Neurol Disord· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial.
Ludwig Kappos, Hans-Peter Hartung, Mark S Freedman, Alexey Boyko, Ernst Wilhelm Radü, Yann Hyvert

Lancet Neurol· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of the Spatzle Pro-domain in the generation of an active toll receptor ligand.
Alexander N R Weber, Monique Gangloff, Martin C Moncrieffe, Yann Hyvert, Jean-Luc Imler

J Biol Chem· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Weckle is a zinc finger adaptor of the toll pathway in dorsoventral patterning of the Drosophila embryo.
Li-Ying Chen, Juinn-Chin Wang, Yann Hyvert, Hui-Ping Lin, Norbert Perrimon

Curr Biol· June 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis